Stem Cell–Derived Retinal Sheets Enter Clinical Trial for Retinitis Pigmentosa

A groundbreaking clinical trial is underway in the U.S. to explore whether stem cell–derived retinal sheets can help preserve or restore vision in people with retinitis pigmentosa (RP) . The study is sponsored by Sumitomo Pharma America, Inc. and represents one of the most advanced attempts yet to bring stem cell therapies into clinical practice for inherited retinal diseases. What Is Being Tested? The investigational therapy, DSP-3077 , uses retinal tissue created from induced pluripotent stem cells (iPS cells) donated from healthy individuals. Scientists reprogram these cells into a sheet of retinal cells, which is then surgically implanted beneath the retina. Unlike gene therapies that target specific mutations, this approach could potentially benefit people with any form of RP , regardless of their genetic profile. How the Trial Works One-time surgery : DSP-3077 is delivered into the subretinal space through a surgical procedure. Immune protection : Patients receive temporary immunosuppressive treatment to help the transplanted cells survive and integrate. Long-term follow-up : P